SCHEMBL7094153

SCHEMBL7094153

O=C1CCN(Cc2cccc3ccccc23)C(=O)[C@H](Cc2cccc(Cl)c2)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ OPRK1 P41145 3/20 0.42
▸ MAPT P10636 3/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ SSTR1 P30872 1/20 0.40
▸ SSTR2 P30874 1/20 0.40
▸ SSTR4 P31391 1/20 0.40
▸ SSTR3 P32745 1/20 0.40
▸ SSTR5 P35346 1/20 0.40
▸ OPRM1 P35372 1/20 0.39
▸ CLPP Q16740 1/20 0.39
▸ HDAC6 Q9UBN7 3/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.38
▸ CCR4 P51679 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5239008 0.90 CLPP (0.42) L3MBTL1OPRK1MAPTMEN1KMT2A
SCHEMBL5232940 0.89 TACR2 (0.43) L3MBTL1OPRK1MAPTMEN1KMT2A
SCHEMBL5229554 0.89 TACR2 (0.43) L3MBTL1OPRK1MAPTMEN1KMT2A
SCHEMBL5234092 0.79 KMT2A (0.67) L3MBTL1MAPTMEN1KMT2ASSTR1
SCHEMBL5230507 0.78 MAPT (0.43) L3MBTL1OPRK1MAPTMEN1KMT2A
SCHEMBL877505 0.77 DDB1 (0.57) L3MBTL1OPRK1CYP2C19HDAC6HDAC1
SCHEMBL877537 0.77 DDB1 (0.57) L3MBTL1OPRK1CYP2C19HDAC6HDAC1
SCHEMBL7536713 0.75 CCR4 (0.37) L3MBTL1MAPTMEN1KMT2ASSTR1
SCHEMBL7536717 0.75 CCR4 (0.37) L3MBTL1MAPTMEN1KMT2ASSTR1
SCHEMBL5232904 0.74 TACR2 (0.39) OPRK1OPRM1HDAC6SIGMAR1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US claimed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US claimed
EP-1296961-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-02 — — EP disclosed
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US disclosed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US disclosed
WO-2001090083-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation BDKRB2, NPSR1, BDKRB1 L3MBTL1 4081/4885OPRK1 128/4885MAPT 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback